Novel KRAS Drug Shows 'Excellent' Efficacy in Tough-to-Treat Lung Cancer

(MedPage Today) -- SAN DIEGO -- Investigational zoldonrasib was well tolerated and showed encouraging clinical activity in previously treated KRAS G12D-mutated non-small cell lung cancer (NSCLC), according to a phase I study. Among patients...
Source
MedPage Today
Opens original article in a new tab



